A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase
1b study of LY2584702 in combination with either erlotinib or everolimus.